10-Q: SCWorx Reports Deepening Losses, Nasdaq Delisting Risk

SCWorx Corp. reported a significant increase in net loss for Q2 2025, alongside declining revenue and a going concern warning, while facing Nasdaq delisting for its low share price.

Summary

• Net loss for the three months ended June 30, 2025, significantly widened to $1,906,085, compared to $337,313 for the same period in 2024.
• Revenue decreased by 8.0% to $682,632 for Q2 2025, down from $742,027 in Q2 2024, primarily due to expiration and non-renewal of customer contracts.
• For the six months ended June 30, 2025, net loss increased to $2,382,388, compared to $515,972 for the same period in 2024.
• Revenue for the six months ended June 30, 2025, decreased by 9.7% to $1,402,931, down from $1,554,126 in the prior year period.
• Gross profit declined by 26.7% for the three-month period and 30.3% for the six-month period year-over-year.
• Operating expenses decreased for the three-month period due to lower legal and professional fees, but increased slightly for the six-month period due to higher marketing and sales efforts.
• Other expenses surged due to non-cash interest expense and amortization of debt discounts from new convertible notes.
• Cash balance increased to $340,209 as of June 30, 2025, from $106,654 at December 31, 2024, primarily due to proceeds from new loans.
• The company has an accumulated deficit of $33,358,454 as of June 30, 2025.
• Weighted average common shares outstanding increased significantly to 4,170,341 for Q2 2025 and 3,060,231 for the six months ended June 30, 2025, indicating substantial dilution.
• The company received a Nasdaq minimum bid price deficiency notification on April 16, 2025, and has until October 7, 2025, to regain compliance.
• Disclosure controls and procedures were deemed not effective as of June 30, 2025, due to deficiencies in internal controls and lack of segregation of duties.

Sentiment

Score: 1

Explanation: The company faces severe financial distress with widening losses, declining revenue, a going concern warning, and Nasdaq delisting risk. Significant dilution from convertible debt conversions and ineffective internal controls further compound the negative outlook.

Positives

• Cash balance increased to $340,209 as of June 30, 2025, from $106,654 at December 31, 2024, primarily due to financing activities.
• Operating expenses for the three months ended June 30, 2025, decreased by $79,529, largely due to a reduction in legal and professional fees.

Negatives

• Net loss significantly widened to $1,906,085 for Q2 2025 and $2,382,388 for the six months ended June 30, 2025, compared to prior year periods.
• Revenue declined by 8.0% in Q2 2025 and 9.7% for the six months ended June 30, 2025, primarily due to expiring and non-renewed customer contracts.
• Gross profit decreased by 26.7% in Q2 2025 and 30.3% for the six months ended June 30, 2025.
• Other expenses increased dramatically due to high non-cash interest expense and amortization of debt discounts from new convertible notes.
• Net loss per share worsened to $(0.46) for Q2 2025 and $(0.78) for the six months ended June 30, 2025.
• Weighted average common shares outstanding increased substantially, indicating significant shareholder dilution.
• The company has an accumulated deficit of $33,358,454 as of June 30, 2025.
• Cash used in operating activities increased to $1,056,454 for the six months ended June 30, 2025, from $340,305 in the prior year period, indicating higher cash burn.

Risks

• Substantial doubt about the ability to continue as a going concern within one year due to recurring operating losses and accumulated deficit.
• Inability to reverse the recent decline in revenue and resume revenue growth.
• Inability to resolve pending litigation proceedings on favorable terms or at all.
• Difficulty obtaining additional financing in sufficient amounts or on acceptable terms to fund the business plan.
• Dependence on third-party subcontractors to perform work on contracts.
• Impact of new or changed laws, regulations, or industry standards that could adversely affect business operations.
• Challenges in adopting and mastering new technologies and adjusting fixed costs to evolving industry and customer demands.
• Impact of changes in general market, economic, and political conditions in the United States and global economies or financial markets.
• Risk of delisting from Nasdaq Capital Market due to failure to maintain a minimum bid price of $1 per share.
• Ineffective disclosure controls and procedures due to deficiencies in internal controls and lack of segregation of duties, which could lead to misstatements in financial reporting.

Future Outlook

Management expects operating losses to continue and will need to generate significant increases in product revenues to achieve profitability. Operating expenses are expected to remain relatively flat during the rest of 2025, with the exception of marketing and advertising. The company is monitoring its common stock trading price and will implement a reverse stock split if necessary to regain Nasdaq minimum bid price compliance by the October 7, 2025 deadline or during a potential extended period.

Management Comments

• "We have suffered recurring losses from operations and incurred a net loss of $2,382,388 for the six months end June 30, 2025 and $1,136,225 for the year ended December 31, 2024. The accumulated deficit as of June 30, 2025 was $33,358,454. The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations."
• "These conditions indicate that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the financial statement issuance date."
• "We expect operating expenses to remain relatively flat during the rest of 2025 with the exception of marketing and advertising."
• "If compliance with the minimum bid price requirement is not regained within the 180-day period, the Company will implement a reverse stock split within the range previously approved by its shareholders."
• "Due to deficiencies in the design of internal controls and lack of segregation of duties, our Disclosure Controls were not effective as of June 30, 2025."

Industry Context

SCWorx operates in the healthcare information technology sector, providing data content, normalization, interoperability, and big data analytics solutions to hospitals and health systems. This sector is generally characterized by increasing demand for efficient data management and analytics to improve healthcare processes and reduce costs. However, SCWorx's declining revenue and significant losses suggest it is struggling to capture market share or retain existing contracts within this competitive landscape, potentially lagging behind industry growth trends or failing to adapt to evolving customer needs effectively.

Comparison to Industry Standards

• SCWorx's recurring losses and accumulated deficit of over $33 million indicate a significant deviation from the profitability and financial stability typically expected of established SaaS providers in the healthcare IT space. Comparable companies like Health Catalyst (HCAT) or Allscripts (MDRX, now part of Veradigm) generally demonstrate more stable or growing revenue streams and clearer paths to profitability, or are already profitable.
• The decline in revenue due to 'expiration and non-renewal of certain customer contracts' suggests a struggle with customer retention or competitive pricing, which is a critical metric for SaaS businesses. Leading SaaS companies typically boast high retention rates (e.g., 90%+ net retention) and consistent revenue growth.
• The substantial doubt about the company's ability to continue as a going concern is a severe red flag, contrasting sharply with the financial health of most publicly traded healthcare IT firms that typically have stronger balance sheets or clear funding pathways.
• The significant increase in shares outstanding due to convertible debt conversions (over 4 million shares in six months) and legal settlements points to heavy dilution, which is far more aggressive than typical capital raises seen in healthier industry peers, often indicating distress financing.
• The disclosure of 'not effective' disclosure controls and procedures due to 'deficiencies in the design of internal controls and lack of segregation of duties' is a serious corporate governance issue, falling well below the standards expected for a publicly traded company, especially when compared to robust internal control frameworks at larger, more mature healthcare IT companies.

Corporate Governance

Legal Proceedings

• CorProminence d/b/a Core IR v. SCWorx AAA Arbitration Case 01-22-0001-5709: An arbitrator awarded Core IR $461,856 on October 16, 2023, which resulted in a judgment of approximately $502,000 including interest. The company settled this by issuing common stock valued at $502,000 in tranches, with the final issuance on May 21, 2025.

Related Party Transactions

• A payable of $149,838 was due to an officer for contract work performed prior to becoming an officer as of June 30, 2025, and December 31, 2024.
• A shareholder advance of $100,000 from the company's former CEO and shareholder, made in September 2021, was fully remitted as of June 30, 2025.
• The company's CFO advanced an aggregate of $128,479 in cash between January 18, 2024, and July 11, 2024, which was fully repaid as of December 31, 2024.

Stakeholder Impact

• Shareholders: Significant dilution due to issuance of common stock for convertible loan conversions and legal settlements. Risk of total loss of investment due to going concern issues and potential Nasdaq delisting. Share price likely to be negatively impacted by poor financial results and governance issues.
• Creditors (Convertible Note Holders): Secured by all company assets, but the company's going concern doubt and recurring losses indicate high risk. Conversion features allow them to become shareholders, potentially mitigating some credit risk but exposing them to equity risk.
• Employees: Staffing fluctuations mentioned in cost of revenues, and increased salaries and wages suggest some changes in compensation or headcount, but overall job security may be at risk given the company's financial instability.
• Customers: Declining revenue due to 'expiration and non-renewal of certain customer contracts' suggests potential dissatisfaction or competitive pressures, which could impact future service reliability or product development.
• Management: Faces significant challenges in turning around the company's financial performance, regaining Nasdaq compliance, and addressing internal control deficiencies.

Next Steps

• Regain compliance with Nasdaq's $1 minimum bid price requirement by October 7, 2025, or seek an extension.
• Implement a reverse stock split if necessary to meet Nasdaq's minimum bid price requirement.
• Generate significant increases in product revenues to achieve profitability and address going concern issues.
• Address deficiencies in the design of internal controls and lack of segregation of duties to improve disclosure controls and procedures.

Key Dates

Recommendation

The company is in severe financial distress, evidenced by widening net losses, declining revenue, and a formal 'going concern' warning. The significant increase in shares outstanding due to convertible debt conversions and legal settlements indicates substantial dilution for existing shareholders. Furthermore, the Nasdaq minimum bid price deficiency and ineffective internal controls highlight critical operational and governance failures. There is no clear path to profitability or sustainable operations presented, making the stock a high-risk, low-reward investment. Investors face a high probability of further capital erosion and potential delisting.

Keywords

Healthcare IT, Data Normalization, Interoperability, Big Data Analytics, SaaS, Hospital Solutions, Supply Chain Management, Revenue Cycle Management, SEC Filing, 10-Q, Going Concern, Nasdaq Compliance, Convertible Debt